Making NEWS ‘Brown Fat’ Is Believed to Be a Wondrous Tissue That Burns Energy to Generate Heat, That Could Help Us Fi Ght Obesity

Total Page:16

File Type:pdf, Size:1020Kb

Making NEWS ‘Brown Fat’ Is Believed to Be a Wondrous Tissue That Burns Energy to Generate Heat, That Could Help Us Fi Ght Obesity breakthrough December 2011 | Issue 18 Professor John Mattick AO FAA Image courtesy of Paul Harris, The Garvan Institute of Medical seesaw photography Research recently announced the appointment of Professor John Mattick AO FAA as the Institute’s next Executive Director, following the retirement of Professor John Shine AO FAA. Professor Mattick will begin his tenure at Garvan in January 2012, and is taking every opportunity in the lead-up to his arrival to meet Garvan staff , board members and supporters. Read more about Professor Mattick, his impact on medical research, and his hopes for his time at the Garvan on page 5. Making NEWS ‘Brown fat’ is believed to be a wondrous tissue that burns energy to generate heat, that could help us fi ght obesity. We are obese when we have too much ‘white fat’, which is basically an organ of energy storage. In contrast, brown fat is like a heat generator. Around 50g of white fat stores 300 kilocalories of energy. The same amount of brown fat burns 300 kilocalories a day. Garvan researchers have shown that brown fat can be grown in culture from stem cells biopsied from adults – giving hope that one day we might be able to either grow someone’s brown fat outside the body and then transplant it, or else stimulate its growth using drugs. Identical twins have identical genomes, but that is where Inside this issue: it stops. There are subtle diff erences in their personalities, how they look, how they act and in their susceptibility From the CEO 2 to disease. How can this be? According to scientists Opinion 2 from Garvan and Queensland Medical Research Institute, it all depends on how the “epigenome” is modifi ed Garvan welcomes Professor John Mattick 3 by the environment. More specifi cally, it depends on exactly how particular parts of the genome are aff ected Cures can take more than a lifetime 4 by ‘methylation’, or the attachment of hydrocarbon Type 2 diabetes 5 molecules - ‘methyl groups’, that literally change the voice of the genome, silencing some genes and Staff profi le – Dr Ann McCormack 6 amplifying others. These fi ndings are based on an eight- year study involving 512 adolescent twins (128 identical Fundraiser profi le – ‘Team Phil’ 6 twin pairs, as well as 128 non-identical twin pairs), with an Ask Garvan 7 average age of 14.15 years. First glimpse inside the Kinghorn Cancer Centre 7 Garvan scientists have discovered that a single gene In memory of a remarkable man 7 controls a very complex process, apparently forming the crucial link between eating a high fat diet and developing Clinical studies 8 diabetes. Compounds are already being developed for blocking the gene – known as Id1 – as it has known Coming up 8 adverse eff ects in cancer. This drug development work In memoriam 8 would very much shorten the path from discovery to prospective treatment in the case of Type 2 diabetes. breakthrough From the CEO Opinion Welcome to the fi nal issue of breakthrough for the year. As you will read, we have some very exciting news with the appointment of our new Executive Director, Professor John Mattick AO FAA who is joining us early in As I retire as Executive Director at the end of the year, I 2012. Professor Mattick has an outstanding take this opportunity to refl ect on the past 20 years at this reputation as one of Australia’s leading remarkable institution. I have been extremely privileged scientists and will bring a wonderful range to be at the Garvan and to witness fi rsthand the many of skills to the Garvan. exciting research discoveries that have emanated from I am sure that many of our supporters will be the institute. It clearly is an institute that should make all delighted to know that our current Executive Australians very proud and I have been continually humbled Director, Professor John Shine will not be by observing every day the generosity of our supporters and going very far way – in fact, he won’t even the dedication, intelligence, creativity and commitment of all be leaving the building! Professor Shine the staff . While we all appreciate our good fortune working will return to the lab to further pursue his in research, we are all very aware of the responsibility that passion for medical research. comes with it – to ensure that the critical trust and support As the year draws to a close, it is wonderful of our community is honoured by a focus on producing the to look back at some of the amazing very best research and a focus on delivering improved health breakthroughs that have been made here outcomes for all. at Garvan in areas as diverse as pancreatic Although the past 20 years has seen amazing progress, cancer, childhood deafness, asthma and the next decade promises even more. The Garvan has been Type 2 diabetes (to name a few!) most fortunate to attract Professor John Mattick as the next The year has also been great personally Executive Director. John is an outstanding Australian and for some of our researchers who have won an international leader in the analysis and understanding of prestigious awards. Congratulations to Dr the human genome – the area which is truly bringing us into Alex Swarbrick who received the Cancer the era of personalised medicine. Under John’s leadership Institute of NSW’s 2011 Premier’s Fellow of and with your ongoing support, the exciting growth planned the Year Award and Dr David Chang who for Garvan (the fi rst example being the Kinghorn Cancer received the CINSW 2011 Premier’s Scholar Centre), will rapidly come to fruition. of the Year Award, as well as a Pfi zer Oncology International Studentship. To all our wonderful supporters – thank you for helping Garvan continue its vital, world- class work in 2011, and we look forward to your ongoing support in 2012. My best wishes to you and your loved ones for a safe and enjoyable festive season. Yours sincerely, Andrew Giles Garvan Research Foundation Professor John Shine AO FAA Executive Director December 2011 | Issue 18 3 Welcome: AO FAA Professor John Mattick Garvan welcomes new “After heading IMB and its forebear for Executive Director, 18 years, I realised Professor John Mattick that I had three big AO FAA jobs. I was running an institute of over 400 Professor John Mattick, holder of people. I had research a prestigious NHMRC Australia I wanted to pursue, Fellowship at the University of because I thought I Queensland and the inaugural had seen something Director of the University’s Institute nobody else had - that of Molecular Bioscience (IMB), has human genetics had been misunderstood been appointed as Garvan’s new for the past 50 years. I Executive Director. also had an extremely Professor Mattick is excited to be supportive family that joining Garvan, which he considers I wanted to give more to be an outstanding medical time to. I was confi dent research institute. He also believes it that I could do any to be best placed to lead Australia two of those jobs well. into the next generation of medical However, by trying research. to do all three, I was compromising all of Although currently residing in them. Brisbane, Professor Mattick is a born “There was really no and bred Sydney-sider. Professor John Mattick AO FAA choice. In 2006 I elected to go Image courtesy of Paul Harris, seesaw photography “I grew up here, mainly in the inner back to research for a while, as I did west. I lived for a while as a student not want to die wondering,” said of our development and cognitive at the bohemian (Woolloomooloo) Professor Mattick. complexity. It also opens many end of Victoria Street,” (the same avenues for entirely novel It is this research that has street on which Garvan is located). therapeutic approaches. transformed the way scientists now In 1988, Professor Mattick was lured think about the human genome, our Of Garvan’s future, Professor to Queensland by an invitation evolution and our brain. Previously, Mattick says, “There is presently from the University of Queensland it was believed that only a few per a great opportunity to do ‘next to apply for a Foundation cent of the genome (the protein- generation’ science and medicine, Professorship in Molecular Biology, coding part and nearby regulatory using the amazing advances in and at the same time, to start a new sequences) was actually useful. The technology that have occurred over centre in molecular biology. rest was labeled “Junk DNA”. By the past decade, especially in DNA challenging this long-held belief, sequencing, and thereby to connect “By the end of the fi rst fi ve years, Professor Mattick was able to our capabilities directly with the we were self-suffi cient. A few years show that this “Junk DNA” actually health and medical concerns of the later, we had more research income specifi es a massive hidden layer of community. I think this will be the than another local university. It was regulation that directs the processes true fl owering of medical research due to the vision we set out and of our development from a single institutes, and I want Garvan, judicious appointments of gifted cell to a fi nely sculpted organism of through its close collaboration people. This is a great formula, 100 trillion cells that can walk and with St Vincent’s Hospital, and and the Centre matured into the talk. This insight has made scientists the opportunities presented by the Institute for Molecular Bioscience re-think biology and consider a joint Kinghorn Cancer Centre, to (IMB), now recognised as one of previously unknown level of the lead the way.” Australia’s best.
Recommended publications
  • Deptbiochemistry00ruttrich.Pdf
    'Berkeley University o'f California Regional Oral History Office UCSF Oral History Program The Bancroft Library Department of the History of Health Sciences University of California, Berkeley University of California, San Francisco The UCSF Oral History Program and The Program in the History of the Biological Sciences and Biotechnology William J. Rutter, Ph.D. THE DEPARTMENT OF BIOCHEMISTRY AND THE MOLECULAR APPROACH TO BIOMEDICINE AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO VOLUME I With an Introduction by Lloyd H. Smith, Jr., M.D. Interviews by Sally Smith Hughes, Ph.D. in 1992 Copyright O 1998 by the Regents of the University of California Since 1954 the Regional Oral History Office has been interviewing leading participants in or well-placed witnesses to major events in the development of Northern California, the West, and the Nation. Oral history is a method of collecting historical information through tape-recorded interviews between a narrator with firsthand knowledge of historically significant events and a well- informed interviewer, with the goal of preserving substantive additions to the historical record. The tape recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is indexed, bound with photographs and illustrative materials, and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable.
    [Show full text]
  • 2011 Annual Report
    Mission 02 Who we are, What we do 03 Reports Chairman's Report 04 Executive Director's Report 06 Garvan Research Foundation Chairman's Report 08 Professor John Mattick 10 Garvan at a Glance Organisation Chart 13 Patent Portfolio by Category 14 Scientific Publications 14 Philanthropic Support 14 Staff Profile 15 Operating Income 15 Peer Reviewed Grant Income 15 Research Collaborations 17 Research Highlights 19 Research Programs & Initiatives Cancer Program 20 The Kinghorn Cancer Centre 28 Diabetes & Obesity Program 30 Diabetes Vaccine Development Centre 36 Immunology Program 38 Neuroscience Program 44 Professor Peter Croucher 50 Osteoporosis & Bone Biology 52 Core Research Facilities 57 Management Highlights 58 Business Development 59 Garvan Community Life Governors 61 Partners for the Future 61 Volunteers 62 Garvan Supporters 62 Garvan Gala Supporters 65 Bequests 65 Governance Garvan Institute 67 Garvan Research Foundation 70 Publications 73 Financial Highlights Income Statement 85 Balance Sheet 86 Garvan Research Foundation Statement of Funds 87 Garvan's mission is to make significant contributions to medical research that will change the directions of science and medicine and have major impacts on human health. Garvan strives to enhance and develop research programs that combine fundamental science with strong clinical interactions. The Garvan Institute of Medical Research Significant breakthroughs have been is a world leader in its field, pioneering achieved by Garvan scientists in the study into some of the most widespread understanding and treatment of diseases diseases affecting our community today. such as: Research at Garvan is focused upon understanding the role of genes in health _ Cancer and disease as the basis for developing _ Diabetes and obesity future cures.
    [Show full text]
  • EMBL in Australia EMBL in Italy Friday,Dedicated 9 June To2017 Riccardo Cortese 13:30 –19:00Friday 5 May 2017, 10:30-19:00
    EMBL in Australia EMBL in Italy Friday,Dedicated 9 June to2017 Riccardo Cortese 13:30 –19:00Friday 5 May 2017, 10:30-19:00 Venue: The Garvan Institute of Medical Research Venue: TIGEM (Auditorium) in Pozzuoli, near Naples John Shine Meeting Room, Level 6 of The Kinghorn Via Campi Flegrei 34, 80078 Cancer Centre, 370 Victoria Street, Darlinghurst [email protected] PROGRAMME 10:30-11:00 Welcome networking 11:00-11:30 In memory of Riccardo Cortese Friday 9 June Phil Avner, Head, EMBL Monterotondo Andrea Ballabio, Scientific Director, TIGEM 13:30–14:00 Welcome Coffee Alfredo Nicosia, CSO & Co-founder, Okairos 14:00–15:00 EMBL and EMBL Australia Partnership 11:30-12:30 Research at EMBL Phil Avner,John Head, Mattick EMBL Monterotondo Jamie Hackett,Executive Group Director, Leader, Garvan EMBL Institute Monterotondo Paul Heppenstall,Silke Schumacher Group Leader, EMBL Monterotondo DiscussionDirector International Relations, EMBL, Heidelberg James Whisstock 12:30-13:30 ResearchScientific at TIGEM Head, EMBL Australia Partnership GracianaNHMRC Diez Roux,Senior ChiefPrincipal Scientific Research Officer, Fellow, TIGEM Monash University Andrea Ballabio, Scientific Director, TIGEM Katharina Gaus Antonella De Matteis, Cell Biology programme coordinator, TIGEM Head, EMBL Australia Node in Single Molecule Science Carmine Settembre, Assistant investigator, TIGEM NHMRC Senior Research Fellow, University of New South Wales Diego Medina, Head, High Content Screening Facility, TIGEM 15:00–15:30 Coffee 13:30-15:00 Lunch and tour of TIGEM labs 15:30–16:50 EMBL Alumni Research 15:00-16:00 Resources in Italy Marco Foiani,Sean O’ Scientific Donoghue Director, IFOM FedericoGroup Caligaris-Cappio, Leader and Senior Scientific Faculty Director, Member, AIRC Garvan Institute Lucia Faccio,Chief Executive Director Scienceof Business Leader, Development, CSIRO Telethon Mirana Ramialison 16:00-16:30 CoffeeGroup Leader, Australian Regenerative Medicine Institute, Monash University 16:30-17:30 ResearchMichael of EMBL Parker alumni GennaroDirector, Ciliberto, St.
    [Show full text]
  • 1 Early Recombinant Protein Therapeutics Pierre De Meyts1,2,3
    3 1 Early Recombinant Protein Therapeutics Pierre De Meyts1,2,3 1Department of Cell Signalling, de Duve Institute, Catholic University of Louvain, Avenue Hippocrate 75, 1200, Brussels, Belgium 2De Meyts R&D Consulting, Avenue Reine Astrid 42, 1950, Kraainem, Belgium 3Global Research External Affairs, Novo Nordisk A/S, 2760, Måløv, Denmark 1.1 Introduction The successful purification of pancreatic insulin by Frederick Banting, Charles Best, and James Collip in the laboratory of John McLeod at the University of Toronto in the summer of 1921 [1–3], as reviewed in the magistral book of Bliss [4], ushered in the era of protein therapeutics. Banting and McLeod received the Nobel Prize in Physiology or Medicine in 1923. The discovery of insulin was truly a miracle for patients with Type 1 diabetes, for whom the only alternative to a quick death from ketoacidosis was the slow death by starvation on the low-calorie diet prescribed by Allen of the Rockefeller Institute [5–7]. Insulin went into immedi- ate industrial production (from bovine or porcine pancreata) from the Connaught laboratories of the University of Toronto and, under license from the University of Toronto by Eli Lilly and Co. in the United States, by the Danish companies Nordisk Insulin Laboratorium and Novo (who merged in 1989 as Novo Nordisk), and by the German company Hoechst (now Sanofi), all of which remain the major players in the insulin business today. Insulin also turned out to be a blessing for scientists interested in protein struc- ture. It was the first protein to be sequenced [8, 9], earning Fred Sanger his first Nobel Prize in 1958.
    [Show full text]
  • Annual Report 2013–2014
    MUSEUM OF APPLIED ARTS AND SCIENCES ANNUAL REPORT 2013–2014 POWERHOUSE MUSEUM SYDNEY OBSERVATORY POWERHOUSE DISCOVERY CENTRE The Hon Troy Grant MP Minister for the Arts Parliament House Sydney NSW 2000 Dear Minister On behalf of the Board of Trustees and in accordance with the Annual Reports (Statutory Bodies) Act 1984 and the Public Finance and Audit Act 1983, we submit for presentation to Parliament the Annual Report of the Museum of Applied Arts and Sciences for the year ending 30 June 2014. Yours sincerely Prof John Shine AO, FAA Rose Hiscock President Director ISSN 0312–6013 © Trustees of the Museum of Applied Arts and Sciences 2014 Compiled by Peter Morton The Museum of Applied Arts and Sciences is a statutory authority of, and principally funded by, the NSW State Government. 2 CONTENTS PRESIDENT’S FOREWORD 4 DIRECTOR’S REPORT 5 GOVERNANCE 6 THE YEAR IN REVIEW 7 OUR AUDIENCES 2013–14 10 ORGANISATION CHART 12 DEPARTMENT REPORTS 13 Curatorial, Collections and Exhibitions 13 Programs and Engagement 14 Corporate Resources 17 Development and External Affairs 18 ON-SITE EXHIBITIONS AND DISPLAYS 19 MUSEUM OUTREACH 20 STAFF SCHOLARSHIP AND COMMUNITY 22 ENGAGEMENT Staff professional commitments 22 Staff lectures and presentations off site 23 FINANCES: THE YEAR IN REVIEW 25 FINANCIAL REPORT 26 APPENDICES 63 1. Board of Trustees 63 2. Principal Offi cers 63 3. Off-site exhibitions 64 4. Staff overseas travel 64 5. Staffi ng by department 65 6. EEO statistics 66 7. SES positions 67 8. Audit Attestation 67 9. ICT Attestation 68 10. Life Fellows 68 11.
    [Show full text]
  • Shine-Dalgarno Anti-Shine-Dalgarno Sequence Interactions and Their Functional Role in Translational Efficiency of Bacteria and Archaea
    Shine-Dalgarno Anti-Shine-Dalgarno Sequence interactions and their functional role in translational efficiency of Bacteria and Archaea Akram Abolbaghaei Supervisor: Dr. Xuhua Xia Thesis submitted to the Faculty of Graduate and Postdoctoral Studies University of Ottawa In partial fulfillment of the requirements for a Master’s degree from the Ottawa-Carleton Institute of Biology Thèse soumise à la Faculté des Etudes Supérieures et Postdoctorales Université d’Ottawa En vue de l’obtention de la maîtrise L’Institut de Biologie d’Ottawa-Carleton © Akram Abolbaghaei, Ottawa, Canada, 2016 Abstract Translation is a crucial factor in determining the rate of protein biosynthesis; for this reason, bacterial species typically evolve features to improve translation efficiency. Biosynthesis is a finely tuned cellular process aimed at providing the cell with an appropriate amount of proteins and RNAs to fulfill all of its metabolic functions. A key bacterial feature for faster recognition of the start codon on mRNA is the binding between the anti-Shine-Dalgarno (aSD) sequence on prokaryotic ribosomes at the 3’ end of the small subunit (SSU) 16S rRNA and Shine-Dalgarno (SD) sequence, a purine-rich sequence located upstream of the start codon in the mRNA. This binding helps to facilitate positioning of initiation codon at the ribosomal P site. This pairing, as well as factors such as the location of aSD binding relative to the start codon and the sequence of the aSD motif can heavily influence translation efficiency. The objective of this thesis is to understand the SD-aSD interactions and how changes in aSD sequences can affect SD sequences in addition to the underlying impact these changes have on the translational efficiency of prokaryotes.
    [Show full text]
  • Steitz J a & Jakes K. How Ribosomes Select Initiator Regions in Mrna: Base Pair Formation Between the 3' Terminus Of
    ® This Week's Citation Classic Steitz J A & Jakes K. How ribosomes select initiator regions in mRNA: base pair formation between the 3' terminus of 16S rRNA and the mRNA during initiation of protein synthesis in Escherichia coli. Proc. Nat. Acad. Sci. USA 72:4734-8, 1975. [Dept. Vtolec. Biophys. Biochem.. Yale Univ.. New Haven. CT; and Rockefeller Univ., New York, NY] The first experimental evidence was presented to Dalgarno and his student John Shine had supportthe hypothesis that bacterial ribosomes use undertaken the relatively prosaic task of se- base pairing to identify start sites for translation. A quencing the 3 terminal 12 nucleotides of E. coli noncovalent complex including the last 50 nucle- 16S rRNA. Their results conflicted with previous otides of 16S rRNA and an initiator region from an reports, but their corrected sequence exhibited RNA bacteriophage message was generated and limited complementarity to the purine-rich re- characterized. [The SCI® indicates that this paper gions upstream of known initiator AUGs. They has been cited in more than 530 publications.] therefore proposed that the 3' terminus of the 16S rRNA participates in the initiation of protein synthesis by forming several Watson-Crick base 2 mRNA-rRNA Base Pairing During pairs with messenger RNA. Dalgarno's preprint was very exciting, since I knew of many as-yet- Translation Initiation unpublished results that fit perfectly with the Shine-Dalgarno hypothesis. But how could the Joan A. Steitz idea be proven correct? Department of Molecular Biophysics The crucial insight came during a post-Gor- and Biochemistry don Conference hike in the White Mountains Howard Hughes Medical Institute that summer.
    [Show full text]
  • Molecular Cloning and Sequence Analysis of Adult Chicken 0 Globin Cdna Robert I.Richards*''', John Shine't, Axel Ullrich2^, Juli
    volume 7 Number 51979 Nucleic Acids Research Molecular cloning and sequence analysis of adult chicken 0 globin cDNA Robert I.Richards*''', John Shine't, Axel Ullrich2^, Julian R.E.Wells* and Howard M.Goodman^ Downloaded from https://academic.oup.com/nar/article/7/5/1137/2384214 by guest on 27 September 2021 •Department of Biochemistry, University of Adelaide, Box 498, G.P.O., Adelaide, South Australia 5001, and TThe Howard Hughes Medical Institute, Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143, USA Received 4 September 1979 ABSTRACT The molecular cloning and nucleotlde sequence analysis of adult chicken (3 globin mRNA is reported. DNA sequences derived from J_n_ vitro transcription of globin mRNA were purified and amplified as recombinant DNA using the plasmid pBR322. Sequence analysis of several clones coding for 3 globin strongly suggests that transcription errors may be generated near the 5' end of transcripts \n_ vitro by reverse transcription. The complete sequence of the longest S globTn Tnsert containing 51 bases of the 5' untranslated region as well as the complete coding and 3' untranslated regions has been determined. INTRODUCTION The globin gene system, in a variety of species, has become well established as a model for extensive analysis of eukaryote gene expression (3,1*)- This has been mainly due to the accessibility of the structural sequences by mRNA isolation, and the availability of in vivo systems for study such as cultured erythroblasts (5) and Friend erythroleukaemlc cells (6). In view of the available data on the mammalian systems, similar studies of the chicken globin genes will provide information concerning the divergence of structural and putative control regions.
    [Show full text]
  • Hxdocscc UC V. Eli Lilly, Ullrich 1.Pdf 1.2 Mb
    UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF INDIANA INDIANAPOLIS DIVISION IN RE RECOMBINANT DNA TECHNOLOGY ) PATENT AND CONTRACT LITIGATION ) ) MDL Docket No. 912 THE REGENTS OF THE UNIVERSITY OF ) CALIFORNIA ) ) Plaintiff, ) ) CAUSE NO. IP 92-224-C D/G -vs- ) Indianapolis, Indiana ) August 24, 1995 ELI LILLY AND COMPANY, ) Afternoon Session ) Defendant. ) Before the HONORABLE S. HUGH DILLIN TRANSCRIPT OF PROCEEDINGS AT TRIAL •I APPEARANCES: For the Plaintiff: Arthur I. Neustadt Jean-Paul Lavalleye Marc R. Labgold William J. Healey Amy Levinson Kevin Bell Susan B. Tabler For the Defendant: Donald R. Dunner Charles E. Lipsey Amy E. Hamilton John c. Jenkins Jeffrey Karceski Court Reporter: Patricia A. Cline, CM Antonette Thompson, RPR-CSR PROCEEDINGS TAKEN BY MACHINE SHORTHAND • COMPUTER-AIDED TRANSCRIPT 784 1 (Call to order of the Court at 3:55p.m.) 2 PLAINTIFF'S WITNESS, AXEL ULLRICH, SWORN 3 DIRECT EXAMINATION 4 BY MR. LABGOLD: 5 Q. Dr. Ullrich, could you please state your full name for 6 the record. 7 A. My name is Axel Ullrich. 8 Q. Could you spell your last name for the record. 9 A. U-L-L-R-I-C-H. 10 Q. Would you give your current address. 11 A. You want my German address or my American address? 12 Q. Your German 13 A. I have two residences. I have a permanent residence in 14 the United States. My address is 70 Palmer Lane,- in 15 Portola Valley, California 94028; and my German address is 16 Munich, Adalbertstrasse 108, A-D-A-L-B-E-R-T-S-T-R-A-S-S-E 17 108.
    [Show full text]
  • Pnas11052ackreviewers 5098..5136
    Acknowledgment of Reviewers, 2013 The PNAS editors would like to thank all the individuals who dedicated their considerable time and expertise to the journal by serving as reviewers in 2013. Their generous contribution is deeply appreciated. A Harald Ade Takaaki Akaike Heather Allen Ariel Amir Scott Aaronson Karen Adelman Katerina Akassoglou Icarus Allen Ido Amit Stuart Aaronson Zach Adelman Arne Akbar John Allen Angelika Amon Adam Abate Pia Adelroth Erol Akcay Karen Allen Hubert Amrein Abul Abbas David Adelson Mark Akeson Lisa Allen Serge Amselem Tarek Abbas Alan Aderem Anna Akhmanova Nicola Allen Derk Amsen Jonathan Abbatt Neil Adger Shizuo Akira Paul Allen Esther Amstad Shahal Abbo Noam Adir Ramesh Akkina Philip Allen I. Jonathan Amster Patrick Abbot Jess Adkins Klaus Aktories Toby Allen Ronald Amundson Albert Abbott Elizabeth Adkins-Regan Muhammad Alam James Allison Katrin Amunts Geoff Abbott Roee Admon Eric Alani Mead Allison Myron Amusia Larry Abbott Walter Adriani Pietro Alano Isabel Allona Gynheung An Nicholas Abbott Ruedi Aebersold Cedric Alaux Robin Allshire Zhiqiang An Rasha Abdel Rahman Ueli Aebi Maher Alayyoubi Abigail Allwood Ranjit Anand Zalfa Abdel-Malek Martin Aeschlimann Richard Alba Julian Allwood Beau Ances Minori Abe Ruslan Afasizhev Salim Al-Babili Eric Alm David Andelman Kathryn Abel Markus Affolter Salvatore Albani Benjamin Alman John Anderies Asa Abeliovich Dritan Agalliu Silas Alben Steven Almo Gregor Anderluh John Aber David Agard Mark Alber Douglas Almond Bogi Andersen Geoff Abers Aneel Aggarwal Reka Albert Genevieve Almouzni George Andersen Rohan Abeyaratne Anurag Agrawal R. Craig Albertson Noga Alon Gregers Andersen Susan Abmayr Arun Agrawal Roy Alcalay Uri Alon Ken Andersen Ehab Abouheif Paul Agris Antonio Alcami Claudio Alonso Olaf Andersen Soman Abraham H.
    [Show full text]
  • 1 History of Industrial Biotechnology Arnold L
    3 1 History of Industrial Biotechnology Arnold L. Demain, Erick J. Vandamme, John Collins, and Klaus Buchholz 1.1 The Beginning of Industrial Microbiology Microbes have been extremely important for life on Earth. They are the pro- genitors of all life on Earth and are the preeminent system to study evolution. They provide rapid generation times, genetic flexibility, unequaled experimental scale, and manageable study systems. Estimates indicate 5 × 1031 microbial cells exist with a weight of 50 quadrillion metric tons. More photosynthesis is accomplished by microbes than by green plants. More than 60% of the earth’s biomass is that of microbes. Over 90% of the cells in human bodies are microorganisms. Sterile animals are less healthy than those colonized by microbes. Long before their discovery, microorganisms were exploited to serve the needs and desires of humans, that is, to preserve milk, fruits, and vegetables, and to enhance the quality of life with the resultant beverages, cheeses, bread, pickled foods, and vinegar. The use of yeasts dates back to ancient days. The oldest fer- mentation know-how, the conversion of sugar to alcohol by yeasts, was used to make beer in Sumeria and Babylonia before 7000 BC. By 4000 BC, the Egyptians had discovered that carbon dioxide generated by the action of brewer’s yeast could leaven bread. Ancient peoples made cheese with molds and bacteria. Wine was made in China as early as in 7000 BC [1] and in Assyria in 3500 BC. Reference to wine can be found in the Book of Genesis, where it is noted that Noah con- sumed a bit too much of the beverage.
    [Show full text]
  • Terminal Octanucleotide Sequence in 18S Ribosomal
    Biochem. J. (1974) 141, 609-615 609 Printed in Great Britain Identical 3'-Terminal Octanucleotide Sequence in 18S Ribosomal Ribonucleic Acid from Different Eukaryotes A PROPOSED ROLE FOR THIS SEQUENCE IN THE RECOGNITION OF TERMINATOR CODONS By JOHN SHINE and LYNN DALGARNO Department ofBiochemistry, School ofGeneral Studies, Australian National University, Canberra, A.C.T. 2600, Australia (Received 7 January 1974) The 3'-terminal sequence of 18S ribosomal RNA from Drosophila melanogaster and Saccharomyces cerevisiae was determined by stepwise degradation from the 3'-terminus and labelling with [3H]isoniazid. The sequence G-A-U-C-A-U-U-AoH was found at the 3'-terminus of both 18S rRNA species. Less extensive data for 18S RNA from a number of other eukaryotes are consistent with the same 3'-terminal sequence, and an identical sequence has previously been reported for the 3'-end of rabbit reticulocyte 18S rRNA (Hunt, 1970). These results suggest that the base sequence in this region is strongly conserved and may be identical in all eukaryotes. As the 3'-terminal hexanucleo- tide is complementary to eukaryotic terminator codons we discuss the possibility that the 3'-end of 18S rRNA may have a direct base-pairing role in the termination ofprotein synthesis. Termination of protein synthesis in prokaryotes A preliminary account of this work has been pub- occurs in response to the presence of one of the lished (Dalgarno & Shine, 1973). terminator codons (UAA, UAG or UGA) in the ribosomal 'A' site (Haselkorn & Rothman-Denes, Experimental 1973). The terminator triplet is specifically recognized since certain other triplet sequences which do not Media and materials code for any amino acid do not lead to polypeptide cerevisiae were grown release (Bretscher et al., 1965).
    [Show full text]